
[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised azacitidine,
decitabine+cedazuridine and midostaurin for patients with acute myeloid
leukaemia (AML).

Acute myeloid leukaemia and listing dates

Acute myeloid leukaemia (AML) is a type of cancer that affects the blood
and bone marrow.

Listing dates are:

-   azacitidine – 1 February 2011
-   midostaurin – 1 December 2018
-   decitabine+cedazuridine – 1 October 2022

For more information see Written Authority Required Drugs.

Enquiries

-   Transfer enquiries about prescription arrangements to the PBS
    Complex Drugs Programs team and choose the option relevant to the
    condition treated
-   Transfer enquiries about prescription arrangements for
    decitabine+cedazuridine to PBS authority approvals

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
websites.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
